CSD/BSE&NSE/PR/2025-2026
December 11, 2025

To
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai – 400001

Scrip Code: 530239

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: News Release

With reference to above subject, please find enclosed News Release of our company titled **"Suven Life Sciences achieved 100% Patient Enrolment Milestone in Phase-2b Clinical Trial of Ropanicant for Major Depressive Disorder (MDD), more than Two Months Ahead of Schedule"**

This is for your information and record.

Thanking you.
Yours faithfully,
For **Suven Life Sciences Limited**

Shrenik Soni
Digitally signed by Shrenik Soni
Date: 2025.12.11 10:08:38 +05'30'

Shrenik Soni
Company Secretary

Encl.: as above

News Release

Suven Life Sciences achieved 100% Patient Enrolment Milestone in Phase-2b Clinical Trial of Ropanicant for Major Depressive Disorder (MDD), more than Two Months Ahead of Schedule.

Last patient out (LPO) expected by end of February 2026; topline data readout anticipated by May 2026.

Hyderabad, India (11-Dec-2025) - Suven Life Sciences Limited, a clinical-stage biopharmaceutical company focused on discovering and developing innovative treatments for Central Nervous System (CNS) disorders, announced today that its Phase-2b clinical trial of Ropanicant, a nicotinic α4β2 receptor antagonist for treating Major Depressive Disorder (MDD) has successfully achieved its 100% patient enrolment milestone of anticipated randomization, more than two months ahead of schedule. This study is conducted exclusively in USA.

Key Highlights of the Ropanicant Phase-2b Study:

- **Study Design**: The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA for a treatment duration of six weeks. The study will evaluate the efficacy and safety of Ropanicant in patients with MDD, compared to placebo, in improving symptoms of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS). For more information about the Phase-2b study visit ClinicalTrials.gov. Identifier NCT06836063.
- **Enrollment Status**: In less than six months from study initiation, the trial successfully reached its full enrollment target of 195 patients for randomization. The pace of recruitment underscores the strong engagement from both investigators and participating patients.
- **Safety and Tolerability**: Safety data from the study is being monitored continuously, with no significant concerns observed to date.

Suven anticipate topline efficacy and safety results in May 2026.

"*I am deeply grateful to the patients, caregivers, investigators, and our clinical development team for their exceptional commitment in helping us achieve this milestone so rapidly. Together, we are advancing an important scientific effort to evaluate the potential of Ropanicant in patients with MDD. This collective progress moves us closer to delivering new therapeutic options that can meaningfully improve patient lives,*" said Mr. Venkat Jasti, Chairman and Managing Director of Suven Life Sciences.

"Today's milestone represents another exciting step forward as we advance the investigation of Ropanicant in patients with MDD. We reached 100% patient enrolment milestone approximately six months from study initiation, reflecting the high interest from patients and physicians in a potential treatment option with novel mechanism of action. If positive, ropanicant has a potential to transform the lives of people affected by MDD and those around them. Our focus remains on advancing the program efficiently, and we look forward to presenting outcome of this trial by May 2026" said Dr. Ramakrishna Nirogi, President and CSO of Suven Life Sciences.

About Ropanicant (SUVN-911): Ropanicant is a novel, selective a nicotinic α4β2 receptor antagonist in development for MDD. It has shown strong efficacy in animal models of depression and may address key limitations of current treatments, including rapid onset of action, reduced sexual dysfunction, and enhanced cognitive function. Non-clinical safety has been established through extensive pharmacology and toxicity studies (up to 9 months). In Phase-1 trials, Ropanicant was safe and well tolerated at the highest doses, with no significant effects from food or age. The Phase-2a trial demonstrated a favorable safety profile and significant improvements in depressive symptoms, as measured by the MADRS score. Suven fully owns Ropanicant's intellectual property rights.

About Suven Life Sciences: Suven Life Sciences Limited (Suven) is focused on the discovery and clinical development of innovative medicines that address unmet medical needs in CNS disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), Sleep disorders, Major depressive disorders (MDD), Parkinson's disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 5 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (Global Phase-3 study ongoing); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (Phase-2 study for EDS completed; Phase-2 study for Cataplexy and pivotal Phase-3 study for EDS are in planning); Ropanicant (SUVN-911) for MDD (Open-label Phase-2a study completed; Double blind randomized Placebo controlled Phase-2b study ongoing); Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 study in planning), SUVN-I6107 for cognitive disorders (Phase-1 study in progress). In addition to these clinical assets, we have 7 projects in research pipeline across multiple indications. Suven owns all intellectual property rights for its assets in all major markets.

For more information, please visit our website http://www.suven.com

Risk Statement: *Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.*